These findings indicate that blockade of PVRIG not only promotes the anti-tumor immunity of CD8+ T cells, but also unleashes the anti-tumor power of NK cells, therefore making PVRIG a promising immune checkpoint target to treat cancer. This evidence concerns the gene PVRIG and cancer.